Coherus BioSciences to Participate at Upcoming November Investor Conferences

Coherus BioSciences to Participate at Upcoming November Investor Conferences

November 02, 2023 | Last Trade: US$1.67 0.01 -0.60

REDWOOD CITY, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced that senior management will participate in the following investor conferences:

Truist Securities BioPharma Symposium In New York City on Wednesday, November 8, 2023, for 1x1 meetings only.
UBS Biopharma Conference in Miami on Thursday, November 9, 2023, a fireside chat presentation at 11:30 a.m. Eastern Time will be webcast.
6th Annual Evercore ISI HealthCONx Conference in Miami on November 28-30, 2023, a fireside chat presentation on November 30th at 12:30 p.m. Eastern Time will be webcast.

A live audio webcast and an archive of the presentations from UBS Biopharma and Evercore ISI HealthCONx conferences will be available on the investors’ page of the Coherus website at http://investors.coherus.com.

Coherus Contact Information:
Jami Taylor
VP, Investor Relations
This email address is being protected from spambots. You need JavaScript enabled to view it.

Stock Quote

Last Trade:	US$1.67
Daily Change:	-0.01 -0.60
Daily Volume:	459,243
Market Cap:	US$194.100M

August 07, 2025 Coherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update May 27, 2025 Coherus BioSciences Announces Clinical Collaboration with STORM Therapeutics to Evaluate STC-15 in Combination with LOQTORZI® (toripalimab-tpzi) May 12, 2025 Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update April 28, 2025 Coherus BioSciences Presents Promising Early Clinical Data from Phase 1 Dose Expansion Study of CHS-114 in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at AACR 2025 March 25, 2025 Coherus BioSciences to Present Data from a Phase 1 Dose Expansion Study of CHS-114, a Cytolytic Antibody Targeting Chemokine Receptor 8 (CCR8), at the 2025 American Association for Cancer Research (AACR) Annual Meeting LOAD MORE NEWS

Featured Stock

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE